| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 01/02/2002 | EP1165143A2 Method for expressing proteins |
| 01/02/2002 | EP1165139A2 Pharmaceutical compositions comprising in combination a bisphosphonate and a matrix metalloproteinasese inhibitor |
| 01/02/2002 | EP1165132A2 Dry formulation for transcutaneous immunization |
| 01/02/2002 | EP1165114A1 Use of a lectin or conjugates for modulation of c-fibre activity |
| 01/02/2002 | EP1165113A2 USE OF ErbB RECEPTOR LIGANDS IN TREATING DIABETES |
| 01/02/2002 | EP1165112A1 Modulators of polysaccharides and uses thereof |
| 01/02/2002 | EP1165110A2 Antagonists of hmg1 for treating inflammatory conditions |
| 01/02/2002 | EP1165099A2 Methods for limiting scar and adhesion formation |
| 01/02/2002 | EP1165092A1 Cyclopentanone derivatives and their use |
| 01/02/2002 | EP1165088A1 Use of vasopeptidase inhibitors to treat angina pectoris |
| 01/02/2002 | EP1165086A2 Bupropion metabolites and methods of their synthesis and use |
| 01/02/2002 | EP1165085A1 Phthalazine derivatives for treating inflammatory diseases |
| 01/02/2002 | EP1165083A2 Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites |
| 01/02/2002 | EP1165082A1 Inhibitors of prenyl-protein transferase |
| 01/02/2002 | EP1165079A2 Improved dialysis solutions and methods |
| 01/02/2002 | EP1165078A1 Methods of inducing cancer cell death and tumor regression |
| 01/02/2002 | EP1165077A2 Viral treatment |
| 01/02/2002 | EP1165072A2 Valdecoxib compositions |
| 01/02/2002 | EP1165066A1 Use of lipoxin compounds for inhibiting of tnf-(alfa) initiated neutrophil response |
| 01/02/2002 | EP1165064A2 Novel inhibitors of formation of advanced glycation endproducts (age's) |
| 01/02/2002 | EP1165031A1 Resorcinol composition |
| 01/02/2002 | EP1165013A2 Inhibitors of prenyl-protein transferase |
| 01/02/2002 | EP1164844A1 Compositions for aquatic contained in a microparticulate or nanoparticulate vector |
| 01/02/2002 | EP1135151A4 Peptoid and nonpeptoid containing alpha-keto oxadiazoles as serine protease inhibitors |
| 01/02/2002 | EP1079849B1 Use of hmg proteins for the preparation of medicaments having cytotoxic activity |
| 01/02/2002 | EP1073448B1 Fertility improving composition and application thereof |
| 01/02/2002 | EP1011635A4 Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin |
| 01/02/2002 | EP1001801B1 Product comprising at least a double stranded rna combined with at least an interferon for the treatment of viral hepatitis |
| 01/02/2002 | EP0941104A4 Peptide synthesis with sulfonyl protecting groups |
| 01/02/2002 | EP0833843B1 Depigmenting activity of agouti signal protein and peptides thereof |
| 01/02/2002 | EP0785938B1 Fused pyrrolocarbazoles |
| 01/02/2002 | EP0600079B1 Oral 1alpha-hydroxyprevitamin d |
| 01/02/2002 | CN1329620A Analogues of GLP-1 |
| 01/02/2002 | CN1329616A Acylated benzylmal tosides as inhibitors of smooth muscle cell proliferaton |
| 01/02/2002 | CN1329610A Chromenone and chromanone derivatives as integrin inhibitors |
| 01/02/2002 | CN1329609A Tetrahydrobenza epine derivatives useful as modulators of dopamine D3 receptors (antipsychotic agents) |
| 01/02/2002 | CN1329607A Substituted benzopyran analogs for treatment of inflammation |
| 01/02/2002 | CN1329601A New benzimidazolone-benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents |
| 01/02/2002 | CN1329599A 3-substituted-4-arylquinolin-2-one derivatives as potassium channel modulators |
| 01/02/2002 | CN1329597A Pyridinium derivatives for treatment of diabetic and aging-related vascular complications |
| 01/02/2002 | CN1329594A Ureidopiperidine derivatives as selective human NK3 receptor antagonists |
| 01/02/2002 | CN1329593A N-substituted 2-cyanopyrrolidines |
| 01/02/2002 | CN1329589A N-aralkylaminotetralins as ligands for neuroptide YY5 receptor |
| 01/02/2002 | CN1329505A Composition and method for treating allergic diseases |
| 01/02/2002 | CN1329499A Pharmaceutical preparation containing cyclopeptide and chemotherapeutic agent or angiogenesis inhibitor |
| 01/02/2002 | CN1329498A Cancer treatment composition and method using natural plant essential oils |
| 01/02/2002 | CN1329496A Methods and cmpositions for prevention of tolerance to medications |
| 01/02/2002 | CN1329494A Micronized eplerenone compositions |
| 01/02/2002 | CN1329493A Methods and compositions for restoring conformational stability of a protein of the p53 family |
| 01/02/2002 | CN1329491A Aryl and heterocyclyl substituted pyrimidine derivatives as anti-coagulants |
| 01/02/2002 | CN1329490A Composition and method for treating allergic diseases |
| 01/02/2002 | CN1329002A Intermediate product for preparing aralkyl and aryl alkylene heterocyclic lactam and imide |
| 01/02/2002 | CN1328824A Compound for curing female sexual disorder |
| 01/02/2002 | CN1077104C Palladium catalyzed ring closure of triazolyl tryptamine |
| 01/02/2002 | CN1076968C Use of benzo-thiophene compound for preparing medicine for inhibiting bone prosthesis degeneration |
| 01/01/2002 | US6335465 Sterilized 5-aminolevulinic acid |
| 01/01/2002 | US6335459 Prostaglandin i2 receptor modulators; treating tissue necrosis, premature uterine contraction, gastric ulceration, sexual dysfunction, menstrual pain and improper wound healing, immunoregulation, platelet aggregation or neutrophil function |
| 01/01/2002 | US6335457 Complex containing biologically assimilable orthosilicic acid, which is under solid form, stable and concentrated, and a process for preparation of said complex |
| 01/01/2002 | US6335451 Five-membered heterocycles having biphenylsulfonyl substitution, with sulfonylcyanamide side chain, compositions containing them, and methods of using them |
| 01/01/2002 | US6335436 Antisense oligonucleotide coupled to ligand such as d-cycloserine, d-glucosamine, or biotin which binds to receptor on mycobacterium; hybridizes to aspartokinase or aspartate semialdehyde dehydrogenase genes |
| 01/01/2002 | US6335427 Component of stem bromelain |
| 01/01/2002 | US6335360 Indoline-2-carboxylic amide derivatives; obesity, eating and psychological disorders |
| 01/01/2002 | US6335358 Lactacystin analogs |
| 01/01/2002 | US6335354 Aminopyridines and methods of using thereof |
| 01/01/2002 | US6335353 3-hydroxypyridin-4-one derivative; iron deficiency anemia and thalassemia treatment |
| 01/01/2002 | US6335352 Administering heterocyclic cyanoguanidine derivatives as chemokine inhibitors |
| 01/01/2002 | US6335351 Antiulcer agents and antisecretory agents of gastric juice; gastrointestinal disorder and psoriasis treatment; adenosine triphosphatase inhibitors |
| 01/01/2002 | US6335349 Agents that reduce levels of tumor necrosis factor; anticarcinogenic and antiinflammatory agents; treatment of autoimmune diseases |
| 01/01/2002 | US6335346 Pyrrolo-(3,4-b)quinoline derivatives, method for the production and use thereof as a medicament |
| 01/01/2002 | US6335343 Inhibitors of prenyl-protein transferase |
| 01/01/2002 | US6335342 Azaindole derivatives, process for their preparation, and their use as antitumor agents |
| 01/01/2002 | US6335340 compounds of heteroaryl substituted imidazole, their pharmaceutical compositons and uses |
| 01/01/2002 | US6335337 Substituted piperazinones and their therapeutic uses |
| 01/01/2002 | US6335334 Hypertensive agents, anticoagulants; cardiovascular and sexual disorders, angina pectoris, and atherosclerosis |
| 01/01/2002 | US6335332 Barbituric acid derivatives with antimetastatic and antitumor activity |
| 01/01/2002 | US6335331 Antihistamines, antiallergens, brochodilator agents and antispasmodic agents |
| 01/01/2002 | US6335329 Carboxylic acid substituted heterocycles, derivatives thereof and methods of use |
| 01/01/2002 | US6335327 1-benzazepine derivatives; agonists or antagonists of vasopressin and/or oxytocin |
| 01/01/2002 | US6335326 Dopamine agonist and antagonists; central nervous system and psychological disorders; anxiolytic, antidepressant and antiischemic agents; parkinson*s disease |
| 01/01/2002 | US6335195 Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation |
| 01/01/2002 | US6335194 Antisense modulation of survivin expression |
| 01/01/2002 | US6335038 Propionyl l-carnitine and the isoflavone genistein for treatment of osteoporosis and menopause syndrome |
| 01/01/2002 | US6335023 Vehicles and oligosaccharide aldonic acids |
| 01/01/2002 | CA2215333C Heterocyclic substituted piperazinone derivatives as tachykinin receptor antagonists |
| 01/01/2002 | CA2097192C Bombesin antagonists |
| 01/01/2002 | CA2051830C Tricyclic heterocycles |
| 01/01/2002 | CA2042473C Piperidino-nmda antagonists |
| 01/01/2002 | CA2041260C Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents |
| 01/01/2002 | CA2024849C 4-hydroxytetrahydropyran-2-ones and the corresponding dihydroxycarboxylic acid derivatives, salts and esters, process for their preparation, their use as pharmaceuticals, and pharmaceutical preparations and precursors |
| 12/29/2001 | CA2351904A1 Target |
| 12/29/2001 | CA2351902A1 Use of growth hormone secretagogues for stimulating or increasing appetite |
| 12/28/2001 | CA2312644A1 Pharmaceutical compositions and combinations for the treatment or prophylaxis of disorders related to hiv and retrovirus |
| 12/27/2001 | WO2001098518A2 Biotransformation of biologically active compounds made of various classes of chemical substances by means of laccase and manganese peroxidase enzymes |
| 12/27/2001 | WO2001098515A2 Gene-regulating conjugates |
| 12/27/2001 | WO2001098508A2 Transgenic mice containing targeted gene disruptions |
| 12/27/2001 | WO2001098497A1 Secreted epithelial colon stromal-1 polypeptides, nucleic acids encoding the same and uses thereof |
| 12/27/2001 | WO2001098486A1 Mutation associated with epilepsy |
| 12/27/2001 | WO2001098482A2 Liver-specific gene expression cassettes, and methods of use |
| 12/27/2001 | WO2001098478A2 Clk-2, cex-7 and coq-4 genes, and uses thereof |
| 12/27/2001 | WO2001098471A2 Human phosphodiesterases |